SpecificiT Pharma Competitors and Similar CompaniesClear all

SpecificiT Pharma's competitors and similar companies include Greenwich LifeSciences, T3 Pharmaceuticals, CiMaas and Cytovac.
SpecificiT Pharma
SpecificiT Pharma
SpecificiT Pharma a biopharmaceutical company that focuses on developing cellular therapies for hematological cancers.
Greenwich LifeSciences
Greenwich LifeSciences
Greenwich LifeSciences is a clinical-stage biopharmaceutical company.
T3 Pharmaceuticals
T3 Pharmaceuticals
T3 Pharmaceuticals is a biopharmaceutical company developing therapies for cancer patients.
CiMaas
CiMaas
CiMaas is a company that develops immunotherapy for cancer by engaging the immune system.
Cytovac
Cytovac
Cytovac is a clinical-stage biopharmaceutical company dedicated to the discovery and development of immunotherapies with a primary focus on orphan diseases.
Founding Date
Founding Date
2016
Founding Date
2006
Founding Date
2015
Founding Date
2015
Founding Date
2008
Type
Type
Private
Type
Public
Type
Private
Type
Private
Type
Private
Tags
Locations
Locations
Montréal, CA HQ
Locations
Stafford, US HQ
Locations
Basel, CH HQ
Locations
Maastricht, NL HQ
Maastricht, NL
Locations
Hørsholm, DK HQ
Employees
Employees
150% decrease
Employees
433% increase
Employees
26
Employees
350% increase
Employees
713% decrease
For sources of this data, please see the company profile

View Company Profiles

Greenwich LifeSciences
HQ
Stafford, US
Employees
4↑ 33% increase

Greenwich LifeSciences is a clinical-stage biopharmaceutical company.

View company
T3 Pharmaceuticals
HQ
Basel, CH
Employees
26

T3 Pharmaceuticals is a biopharmaceutical company developing therapies for cancer patients.

View company
CiMaas
HQ
Maastricht, NL
Employees
3↑ 50% increase

CiMaas is a company that develops immunotherapy for cancer by engaging the immune system.

View company
Cytovac
HQ
Hørsholm, DK
Employees
7↓ 13% decrease

Cytovac is a clinical-stage biopharmaceutical company dedicated to the discovery and development of immunotherapies with a primary focus on orphan diseases.

View company